Arcutis Biotherapeutics (ARQT) said Sunday its preliminary fiscal Q4 revenue is expected to increase by about 366% to $63 million, driven by the demand for Zoryve, a skin disease treatment.
Analysts surveyed by FactSet expect revenue of $56.5 million.
Meanwhile, full-year product revenue is expected to be about $160 million, up by about 449% from a year earlier.
As of Dec. 31, preliminary cash, cash equivalents, restricted cash and marketable securities are expected to be about $229 million.
The company is set to report its fiscal Q4 results on Feb. 25.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。